SEOUL, South Korea I June 02, 2025 I ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S.

Researchers have identified C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cutaneous ...

“INF904 is a promising addition to our pipeline of candidates controlling the terminal complement C5a / C5aR pathway. As an orally administered compound, we plan to study if INF904 is especially ...

InflaRx is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent ...

When complement gets activated, it releases anaphylatoxins C3a and C5a that are potent chemotactic agents. They recruit leukocytes into lesions and also activate cells that express C3a and C5a ...

In the EU, GOHIBIC (vilobelimab) has been granted marketing authorization under exceptional circumstances for the treatment ...

develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression ...

The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3 ...

Complement component 3, often called C3, is an essential protein of the immune system. This protein plays a vital role in the body’s innate immune system, providing: the first line of defense ...